Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AFMD NASDAQ:RLMD NASDAQ:XENE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAFMDAffimed$0.18$0.25$0.07▼$1.13$2.92M2.0751.16 million shsN/ARLMDRelmada Therapeutics$6.55-2.1%$6.93$0.55▼$8.00$689.55M0.391.53 million shs18,653 shsXENEXenon Pharmaceuticals$59.29-0.8%$54.72$30.00▼$63.95$5.73B0.621.34 million shs34,178 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAFMDAffimed0.00%0.00%0.00%0.00%0.00%RLMDRelmada Therapeutics0.00%-0.59%-7.21%+4.86%+996.72%XENEXenon Pharmaceuticals0.00%+12.91%+9.15%+7.54%+84.38%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAFMDAffimed$0.18$0.25$0.07▼$1.13$2.92M2.0751.16 million shsN/ARLMDRelmada Therapeutics$6.55-2.1%$6.93$0.55▼$8.00$689.55M0.391.53 million shs18,653 shsXENEXenon Pharmaceuticals$59.29-0.8%$54.72$30.00▼$63.95$5.73B0.621.34 million shs34,178 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAFMDAffimed0.00%0.00%0.00%0.00%0.00%RLMDRelmada Therapeutics0.00%-0.59%-7.21%+4.86%+996.72%XENEXenon Pharmaceuticals0.00%+12.91%+9.15%+7.54%+84.38%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAFMDAffimed 0.00N/AN/AN/ARLMDRelmada Therapeutics 2.75Moderate Buy$12.0079.37% UpsideXENEXenon Pharmaceuticals 3.00Buy$77.2029.23% UpsideCurrent Analyst Ratings BreakdownLatest RLMD, XENE, and AFMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2026RLMDRelmada Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/18/2026RLMDRelmada Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.006/18/2026RLMDRelmada Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.005/27/2026XENEXenon Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$80.00 ➝ $82.005/12/2026XENEXenon Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$77.00 ➝ $80.005/10/2026XENEXenon Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$69.005/8/2026XENEXenon Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$80.00 ➝ $82.005/8/2026XENEXenon Pharmaceuticals Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$80.00 ➝ $78.004/8/2026XENEXenon Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAFMDAffimed$877K3.33N/AN/A$4.19 per share0.04RLMDRelmada TherapeuticsN/AN/AN/AN/A$1.18 per shareN/AXENEXenon PharmaceuticalsN/AN/AN/AN/A$7.53 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAFMDAffimed-$114.66MN/AN/AN/AN/A-7,836.26%-193.84%-107.24%N/ARLMDRelmada Therapeutics-$57.38M-$1.09N/AN/AN/AN/A-71.22%-64.46%8/6/2026 (Estimated)XENEXenon Pharmaceuticals-$345.91M-$4.70N/AN/AN/AN/A-49.23%-46.42%8/10/2026 (Estimated)Latest RLMD, XENE, and AFMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026RLMDRelmada Therapeutics-$0.18-$0.22-$0.04-$0.22N/AN/A5/7/2026Q1 2026XENEXenon Pharmaceuticals-$1.17-$1.17N/A-$1.17$1.36 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAFMDAffimedN/AN/AN/AN/AN/ARLMDRelmada TherapeuticsN/AN/AN/AN/AN/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAFMDAffimed0.131.931.93RLMDRelmada TherapeuticsN/A18.2518.25XENEXenon PharmaceuticalsN/A27.7927.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAFMDAffimed30.82%RLMDRelmada Therapeutics45.24%XENEXenon Pharmaceuticals95.45%Insider OwnershipCompanyInsider OwnershipAFMDAffimed3.80%RLMDRelmada Therapeutics14.50%XENEXenon Pharmaceuticals4.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAFMDAffimed20016.10 million15.49 millionNo DataRLMDRelmada Therapeutics10104.89 million89.68 millionOptionableXENEXenon Pharmaceuticals21096.67 million92.73 millionOptionableRLMD, XENE, and AFMD HeadlinesRecent News About These CompaniesXenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of "Buy" by AnalystsJune 25, 2026 | americanbankingnews.comXenon Pharmaceuticals Stock Gains 22% in Six Months: Here's WhyJune 23, 2026 | zacks.comCommodore Capital LP Sells 900,000 Shares of Xenon Pharmaceuticals Inc. $XENEJune 18, 2026 | marketbeat.comXenon Pharmaceuticals Inc. $XENE Shares Sold by Polar Capital Holdings PlcJune 17, 2026 | marketbeat.comAvoro Capital Advisors LLC Acquires 24,444 Shares of Xenon Pharmaceuticals Inc. $XENEJune 17, 2026 | marketbeat.comSofinnova Investments Inc. Takes $2.69 Million Position in Xenon Pharmaceuticals Inc. $XENEJune 16, 2026 | marketbeat.comNEXTBio Capital Management LP Takes Position in Xenon Pharmaceuticals Inc. $XENEJune 14, 2026 | marketbeat.comRhenman & Partners Asset Management AB Boosts Holdings in Xenon Pharmaceuticals Inc. $XENEJune 13, 2026 | marketbeat.comAssessing Xenon Pharmaceuticals (XENE) Valuation After Recent Share Price Pullback And Modest Undervaluation EstimateJune 12, 2026 | finance.yahoo.comGillian Cannon Sells 1,190 Shares of Xenon Pharmaceuticals (NASDAQ:XENE) StockJune 9, 2026 | insidertrades.comFiera Capital Corp Boosts Stock Position in Xenon Pharmaceuticals Inc. $XENEJune 9, 2026 | marketbeat.comXenon Pharmaceuticals Inc. $XENE Shares Purchased by Westfield Capital Management Co. LPJune 6, 2026 | marketbeat.comXenon Pharmaceuticals Inc. Rings the Opening BellJune 2, 2026 | nasdaq.comXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 29, 2026 | financialpost.comFXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 29, 2026 | globenewswire.comJPMorgan Raises its Price Target on Xenon Pharmaceuticals (XENE)May 24, 2026 | finance.yahoo.comWhat to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA FilingMay 19, 2026 | finance.yahoo.comXenon Pharmaceuticals Inc. (XENE) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 14, 2026 | seekingalpha.comA Look At Xenon Pharmaceuticals (XENE) Valuation After Phase 3 X TOLE2 Success And Extended Cash RunwayMay 11, 2026 | finance.yahoo.comDid Positive X-TOLE2 Data and a Major Cash Raise Just Shift Xenon Pharmaceuticals' (XENE) Investment Narrative?May 11, 2026 | finance.yahoo.comXenon Highlights Positive Phase 3 Azetukalner Seizure DataMay 8, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRLMD, XENE, and AFMD Company DescriptionsAffimed NASDAQ:AFMDAffimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.Relmada Therapeutics NASDAQ:RLMD$6.55 -0.14 (-2.08%) As of 09:55 AM Eastern This is a fair market value price provided by Massive. Learn more.Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.Xenon Pharmaceuticals NASDAQ:XENE$59.28 -0.46 (-0.76%) As of 09:55 AM Eastern This is a fair market value price provided by Massive. Learn more.Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/22 - 06/26 Rocket Lab's NASA Win Tests Key Support After Sharp Pullback Winnebago Misses Estimates, But Surges 14% After Earnings 3 ETFs Pairing Market-Beating Returns With High Dividend Yields BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone SpaceX Has Real Value—But These 3 Stocks Have Better Odds Right Now Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout 3 Stocks That Could Benefit as the Robotaxi Race Heats Up Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
